Beeline Medicines
Beeline Medicines develops clinical-stage therapies that target immune dysfunction in lupus and other autoimmune and inflammatory diseases.
$300MSeries A
LeadBC
Bain Capital
Activity from announced rounds
Activity in this selectionUnited States · Jul 31, 2025 · Jul 1, 2025
- Rounds participated in
- 1
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $300M 1 disclosed · full round size, not this investor’s share